Keywords
Crohn’s disease, granuloma, vedolizumab, infliximab
Abstract
Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the GI tract, which is frequently associated with extra-intestinal manifestations. Pulmonary parenchymal disease is very uncommon and usually considered to be debilitating and harder to diagnose. Pulmonary granulomas are rarely described in the literature as a complication of Crohn’s disease. Here, we present a patient with Crohn’s disease exacerbation who developed granulomatous lung disease under treatment with vedolizumab. Our case may add evidence to the emerging theory that gut-selective biologic agents could lead to upregulation of some pro-inflammatory factors leading to the evolution of pulmonary disease.
References
![](https://www.ejcrim.com/public/journals/1/submission_2265_1881_coverImage_en_US.jpg)
Views: 994
HTML downloads: 121
PDF downloads: 498
Published:
2021-02-19
Issue:
2021: Vol 8 No 2
(view)